-
UltraSight Advances AI-Enabled Workflows in Cardiac Critical Care
UltraSight has received FDA clearance for PVAD IQ™, a new addition to its Echo Stewardship System designed to support the growing clinical demands of patients on microaxial flow pumps. As use of these devices expands in critical care and high-risk cardiac procedures, PVAD IQ™ enables care teams to access consistent, rapid bedside echocardiography, helping assess…
-
UltraSight™ Receives FDA Clearance to Expand Its AI-Guided Cardiac Echo Stewardship Platform Across Ultrasound Systems
Expanded authorization enables AI-guided FoCUS across devices—supporting consistent diagnostic-quality imaging and cardiology oversight across care settings. BOSTON, MA, UNITED STATES, January 6, 2026 /EINPresswire.com/ — UltraSight™, a leader in AI-guided cardiac imaging workflows, today announced FDA clearance to expand its Echo Stewardship Platform to support compatibility with additional ultrasound system types, including handheld, laptop, and cart-based…
-
UltraSight™ Achieves Enrollment Milestones in Cleveland Clinic and Brigham and Women’s Clinical Studies
UltraSight reaches key study milestones with Cleveland Clinic & Brigham, showing AI can enable any provider to capture diagnostic-quality cardiac images.
-
UltraSight™ Receives KFDA Regulatory Approval for AI Guidance System, Expanding Global Access to Cardiac Imaging
UltraSight™ Secures KFDA Approval for AI-Driven Cardiac Imaging Software in South Korea SEOUL, SOUTH KOREA, June 9, 2025 — UltraSight™, a leader in digital health innovation, announced today that its real-time machine learning guidance software has received regulatory approval from South Korea’s Ministry of Food and Drug Safety (KFDA). The clearance, granted to UltraSight’s joint…
